Evolva enters into collaboration with International Flavors & Fragrances Inc.
Under the multi-year agreement, IFF will fund research and development activities at Evolva, focused primarily on the pathway and yield stages of the program through the scale-up and manufacturing phases. During the collaboration, approximately ten full-time equivalents per year are expected to work on the program. Evolva will receive an upfront technology access fee as well as monthly research fees. In addition, Evolva will receive milestone payments upon achieving certain goals in terms of yield and production volumes. The access fee and the milestone payments will be mid single-digit (USD million) amounts. IFF will commercialize the resulting product and Evolva will receive a royalty on product sales based on both margin and volume.
Neil Goldsmith, CEO & Managing Director of Evolva, said “After FOSU and Abunda, this is our third collaboration in the food ingredient space within a year. We’re very pleased that our synthetic biology platform is increasingly being recognized as useful to design and optimize production routes for products in health and nutrition. We’re looking forward to working with IFF, one of the leading players in the area of flavors and fragrances.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.